Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

CHIESI FARMACEUTICI R&D

Signature(s)

Amount
€ 30,000,000
Countries
Sector(s)
Italy : € 30,000,000
Industry : € 30,000,000
Signature date(s)
3/04/2009 : € 15,000,000
3/04/2009 : € 15,000,000
Link to source
Data sheet
CHIESI FARMACEUTICI R&D
Other links
Summary sheet
Chiesi Farmaceutici Research & Development

Summary sheet

Release date
3 May 2006
Status
Reference
Signed | 03/04/2009
20050111
Project name
Promoter - financial intermediary
Chiesi Farmaceutici Research & Development
Chiesi Farmaceutici SpA is the holding company of a medium-sized privately owned pharmaceutical group based in Parma. The promoter is dedicated to the research, development and commercialisation of products in four core therapeutic areas: respiratory, cardiovascular, musculo-skeletal inflammation and neonatology.
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 30 million
EUR 60 million
Location
Sector(s)
Description
Objectives

The present project represents the first operation with Chiesi Farmaceutici and is aimed at assisting the construction of a new R&D centre as well as the upgrade of the equipment, allowing the rationalization of Chiesi's R&D activities and their future development.

Chiesi is one of the leading pharmaceutical companies in Italy. Although being a mid-sized privately owned group, Chiesi invests every year a significant portion of total turnover (13% in 2004) in R&D. The investments will strengthen the regional and local endowment of R&D and contribute to the EU's private sector investments in R&D, in line with the Bank's i2i plan concerning the promotion and strengthening of scientific research.

Environmental aspects
Procurement

To be verified during appraisal.

To be verified during appraisal.

Comments

Research & Development

Link to source
Summary sheet
Chiesi Farmaceutici Research & Development
Other links
Data sheet
CHIESI FARMACEUTICI R&D

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications